BP793

Budesonide

British Pharmacopoeia (BP) Reference Standard

• Sinónimos: 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
• Fórmula empírica (notación de Hill): C₂₅H₃₄O₆
• Número de CAS: 51333-22-3
• Peso molecular: 430.53
• Número MDL: MFCD00083259
• Código UNSPSC: 41116107
• NACRES: NA.24

Propiedades

• grado: pharmaceutical primary standard
• familia API: budesonide
• Formulario: solid
• caducidad: limited shelf life, expiry date on the label
• fabricante / nombre comercial: BP
• aplicaciones: pharmaceutical; pharmaceutical small molecule
• Formato: neat
• cadena SMILES: [H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@H]5OC(CCC)O[C@@]45C(=O)CO
• InChI: 1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
• Clave InChI: VOVIALXJUBGFJZ-KWVAZRHASA-N
• Información sobre el gen: human ... NR3C1(2908)

Descripción

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Budesonide BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.

Also used in monographs such as:

Budesonide Aqueous Nasal Spray

Budesonide Inhalation Powder, pre-metered

Budesonide Inhalation Powder

Budesonide Pressurised Inhalation

Budesonide Nebuliser Suspension

Acciones bioquímicas o fisiológicas

Budesonide is a second generation glucocorticoid with low systemic absorption. It is used as an anti-inflammatory agent in the treatment of asthma, rhinitis, and inflammatory bowel disease. It inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein in primary human bronchial epithelial cells. Budesonide is currently in clinical trials for the prevention of lung cancer. It shows inhibitory effects on benzo[a]pyrene-induced carcinogenesis of the lung in mice.

Second generation glucocorticoid with low systemic absorption; anti-inflammatory agent; inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein.

Envase

Unit quantity: 110 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia

Otras notas

Sales restrictions may apply.

Información de seguridad

• Pictogramas: GHS08,GHS07
• Palabra de señalización: Danger
• Frases de peligro: H302,H317,H361d,H372,H412
• Consejos de prudencia: P202 - P273 - P280 - P301 + P312 - P302 + P352 - P308 + P313
• Clasificaciones de peligro: Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - Skin Sens. 1 - STOT RE 1 Inhalation
• Órganos de actuación: Adrenal gland
• Código de clase de almacenamiento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable